Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: September 2010
-
By James DeGiulio — Sham Litigation Claims against Par and Paddock Continue in AndroGel Litigation Par Pharmaceutical and Paddock Laboratories received clarification that their agreements with Solvay not to release competing versions of the testosterone supplement AndroGel are still subject to sham litigation claims brought by direct purchasers. In August 2003, Solvay filed patent infringement…
-
By Donald Zuhn — On Monday, the U.S. Patent and Trademark Office announced via a press release and a notice in the Federal Register (75 Fed. Reg. 57261) that it is seeking comments regarding a proposal for incentivizing the creation and wider distribution of humanitarian technologies. In the notice, the Office states that it has…
-
By Donald Zuhn — Biosimilar Approval Pathway: Who Will Be First? Since President Obama signed the Patient Protection and Affordable Care Act into law in March, thereby establishing an approval pathway for biosimilar biological products, interested obsevers have been wondering whether the regulatory pathway would be utilized, and if so, who might be the first…
-
By James DeGiulio — As the Patent Reform Act of 2010 makes its way through the Senate, various groups continue to make their positions known on provisions contained within the legislation. (For a detailed summary of the bill, see "Senate Leadership Unveils Details of Patent Reform Agreement.") On September 12, the Intellectual Property Owners Association…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cancer Research Technology Ltd. et al. v. Sun Pharma Global FZE et al.3:10-cv-04745; filed September 15, 2010 in the District Court of New Jersey • Plaintiffs: Cancer Research Technology Ltd.; Schering Corp.• Defendants: Sun Pharma…
-
September 20, 2010 – Patentable Subject Matter: 35 USC § 101 (George Washington University Law School Intellectual Property Law Program) – Washington, DC September 20-21, 2010 – Patent Litigation 2010 (Practising Law Institute) – San Francisco, CA September 20-22, 2010 – 2nd Annual Business of Biosimilars (Institute for International Research) – Boston, MA September 22-23,…
-
Burrill & Company will be holding its 6th Annual Burrill Personalized Medicine Meeting on September 27-28, 2010 in San Francisco, CA. The meeting will offer presentations on the following topics: • Personalized medicine industry update;• Company presentation: XDx;• Company presentation: Navia Systems;• Panel: Has "healthcare reform" accelerated or decelerated the move to a more personalized…
-
Visiongain will be holding its 7th Annual Biosimilars Conference on October 5-7, 2010 in London, UK. The conference will allow attendees to: • Gain insights of the competitive landscape in biosimilars: U.S., EU, and emerging markets;• Evaluate biobetters and differentiated biosimilars as practical alternatives to biosimilars for regulated markets;• Implement successful commercial models for biobetters…
-
By Kevin E. Noonan — Last week, Judge Claude M. Hilton, District Court Judge for the Eastern District of Virginia, denied APP Pharmaceuticals request to intervene in The Medicines Company's lawsuit against the U.S. Patent and Trademark Office over the timeliness vel non of its Patent Term Extension Request for its patent on the blockbuster…
-
By James DeGiulio — Sandoz, Momenta Fail to Invalidate Teva Patents in Copaxone Suit Teva Pharmaceutical Industries received a favorable ruling in its Copaxone patent infringement suit against Sandoz and Momenta Pharmaceuticals after their motion for summary judgment seeking to invalidate Teva's patents over the drug was denied. In September 2008, Teva brought suit in…
Patent Docs 